Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Heijer, S. Lewington, R. Clarke (2005)
Homocysteine, MTHFR and risk of venous thrombosis: a meta‐analysis of published epidemiological studiesJournal of Thrombosis and Haemostasis, 3
T. Wun, R. White (2009)
Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk FactorsCancer Investigation, 27
J. Ray, C. Kearon, Q. Yi (2007)
Homocystine-lowering therapy and risks for venous thromboembolism: A randomized trialJournal of Vascular Surgery, 46
O. Stanger, B. Fowler, Klaus Piertzik, M. Huemer, E. Haschke-Becher, A. Semmler, S. Lorenzl, M. Linnebank (2009)
Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendationsExpert Review of Neurotherapeutics, 9
P. Jacques, J. Selhub, A. Bostom, P. Wilson, I. Rosenberg (1999)
The effect of folic acid fortification on plasma folate and total homocysteine concentrations.The New England journal of medicine, 340 19
J. Selhub, P. Jacques, P. Wilson, D. Rush, I. Rosenberg (1993)
Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.JAMA, 270 22
L. Brattström, D. Wilcken, J. Öhrvik, L. Brudin (1998)
Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis.Circulation, 98 23
Marshall Stanton (1996)
Homocysteine and cardiovascular diseaseCardiology in Review, 4
J. Finkelstein (1998)
The metabolism of homocysteine: pathways and regulationEuropean Journal of Pediatrics, 157
Takeshi Suzuki, K. Matsuo, K. Hirose, A. Hiraki, T. Kawase, Miki Watanabe, T. Yamashita, H. Iwata, K. Tajima (2008)
One-carbon metabolism-related gene polymorphisms and risk of breast cancer.Carcinogenesis, 29 2
K. Lievers, G. Boers, P. Verhoef, M. Heijer, L. Kluijtmans, N. Put, F. Trijbels, H. Blom (2001)
A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease riskJournal of Molecular Medicine, 79
R. Rozen (1996)
Molecular genetics of methylenetetrahydrofolate reductase deficiency.Journal of inherited metabolic disease, 19 5
W. Hague (2003)
Homocysteine and pregnancy.Best practice & research. Clinical obstetrics & gynaecology, 17 3
A. Bostom, B. Culleton (1999)
Hyperhomocysteinemia in chronic renal disease.Journal of the American Society of Nephrology : JASN, 10 4
D. Kessler, D. Shalala, F. Satchell
Department of Health and Human Services Food and Drug Administration Food Standards: Amendment of Standards of Identity for Enriched Grain Products to Require Addition of Folic Acid
I. Næss, S. Christiansen, P. Romundstad, S. Cannegieter, H. Blom, F. Rosendaal, J. Hammerstrøm (2008)
Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population – results from the HUNT 2 studyBritish Journal of Haematology, 141
(1997)
Homocysteine metabolism: nutritional modulation and impact on health and disease
B. Simone, V. Stefano, E. Leoncini, J. Zacho, I. Martinelli, J. Emmerich, E. Rossi, A. Folsom, W. Almawi, P. Scarabin, M. Heijer, M. Cushman, S. Penco, A. Vayá, P. Angchaisuksiri, G. Okumus, D. Gemmati, S. Cima, N. Akar, Kivilcim Oguzulgen, V. Ducros, C. Lichy, C. Fernández-Miranda, A. Szczeklik, J. Nieto, José Torres, V. Cam-Duchez, P. Ivanov, C. Cantú-Brito, V. Shmeleva, M. Stegnar, D. Ogunyemi, S. Eid, N. Nicolotti, E. Feo, W. Ricciardi, S. Boccia (2013)
Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controlsEuropean Journal of Epidemiology, 28
J. Ray (1998)
Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease.Archives of internal medicine, 158 19
E. López-Quesada, M. Vilaseca, S. González (2000)
[Homocysteine and pregnancy].Medicina clinica, 115 9
Quanshen Yang, L. Botto, M. Gallagher, JM Friedman, C. Sanders, D. Koontz, S. Nikolova, J. Erickson, K. Steinberg (2008)
Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank.The American journal of clinical nutrition, 88 1
L. Botto, Quanhe Yang (2000)
5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review.American journal of epidemiology, 151 9
T. Tsai, Chih‐hsun Yang, C. Chu, Y. Liou, Wen-chin Hsiao, Chien-Ting Lin, L. Wu (2009)
Polymorphisms of MTHFR gene associated with livedoid vasculopathy in Taiwanese population.Journal of dermatological science, 54 3
L. Langman, Joel Ray, J. Evrovski, Erik Yeo, David Cole (2000)
Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study.Archives of internal medicine, 160 7
Lily Wu, James Wu (2002)
Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker.Clinica chimica acta; international journal of clinical chemistry, 322 1-2
N. Radunović, C. Lockwood, O. Stanojlović, M. Sterić, O. Kontić-Vučinić, N. Sulovic, D. Hrnčić, William IV (2015)
Fetal and maternal plasma homocysteine levels during the second half of uncomplicated pregnancyThe Journal of Maternal-Fetal & Neonatal Medicine, 28
P. Jacques, A. Bostom, P. Wilson, S. Rich, I. Rosenberg, J. Selhub (2001)
Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort.The American journal of clinical nutrition, 73 3
S. Hickey, C. Curry, H. Toriello (2013)
ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testingGenetics in Medicine, 15
A. Mansilha, Fernando Araújo, Milton Severo, Sérgio Sampaio, T. Toledo, R. Albuquerque (2005)
Genetic polymorphisms and risk of recurrent deep venous thrombosis in young people: prospective cohort study.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 30 5
R. Rozen (1996)
Annotation Molecular genetics of methylenetetrahydrofolate reductase deficiencyJournal of Inherited Metabolic Disease, 19
M. Cattaneo, Maria Monzani, I. Martinelli, C. Falcon, P. Mannucci (1997)
Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism.Circulation, 97 3
(2009)
The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls
S. Hosseini, E. Kalantar, M. Hosseini, S. Tabibian, M. Shamsizadeh, A. Dorgalaleh (2015)
Genetic risk factors in patients with deep venous thrombosis, a retrospective case control study on Iranian populationThrombosis Journal, 13
P. Nagele, Konrad Meissner, Amber Francis, M. Födinger, N. Saccone (2011)
Genetic and environmental determinants of plasma total homocysteine levels: impact of population-wide folate fortificationPharmacogenetics and Genomics, 21
J. Heit, F. Spencer, R. White (2003)
The epidemiology of venous thromboembolismJournal of Thrombosis and Thrombolysis, 41
Background: Methylene tetrahydrofolate reductase (MTHFR) is a key enzyme in homocysteine metabolism. This study aims to determine the impact of MTHFR polymorphisms on plasma homocysteine levels and risks of venous thromboembolism (VTE). Methods: This retrospective chart review study included a total of 188 subjects who were tested for MTHFR polymorphisms at Metrowest Coagulation Laboratory between April 2011 and April 2016. Two independent coders were trained to extract relevant clinical data for statistical analysis. Results: VTE occurred in 50% of patients with compound mutation, compared with only 28.6% of subjects from the wild-type group. Patients with heterozygous or homozygous A1298C or C677T variants had an intermediate risk of VTE. The median homocysteine level in the wild-type group was slightly lower than that of heterozygous or homozygous MTHFR variants. The difference, however, was not significant (p = 0.6193). Moreover, there was no difference in plasma homocysteine level between patients with VTE versus VTE-free (p = 0.4923). Conclusions: Heterozygous or homozygous MTHFR variants, especially a compound mutation, are associated with increased risk of VTE. Hyperhomocysteinemia does not correlate with MTHFR polymorphisms or VTE risk. Hence, MTHFR genotyping provides more consistent assessment of VTE risk. This information can be incorporated into risk stratification for early intervention and prophylaxis of VTE.
Acta Haematologica – Karger
Published: Jan 1, 2017
Keywords: Homocysteine metabolism; Methylene tetrahydrofolate reductase; Venous thromboembolism
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.